Improving dementia care: The role of screening and detection of cognitive impairment

Soo Borson; Lori Frank; Peter J. Bayley; Malaz Boustani; Marge Dean; Pei Jung Lin; J. Riley McCarten; John C. Morris; David P. Salmon; Frederick A. Schmitt; Richard G. Stefanacci; Marta S. Mendiondo; Susan Peschin; Eric J. Hall; Howard Fillit; J. Wesson Ashford

doi:10.1016/j.jalz.2012.08.008

Improving dementia care: The role of screening and detection of cognitive impairment

Soo Borson, Lori Frank, Peter J. Bayley, Malaz Boustani, Marge Dean, Pei Jung Lin, J. Riley McCarten, John C. Morris, David P. Salmon, Frederick A. Schmitt, Richard G. Stefanacci, Marta S. Mendiondo, Susan Peschin, Eric J. Hall, Howard Fillit, J. Wesson Ashford

Neurology

Research output: Contribution to journal › Comment/debate › peer-review

199 Scopus citations

Abstract

The value of screening for cognitive impairment, including dementia and Alzheimer's disease, has been debated for decades. Recent research on causes of and treatments for cognitive impairment has converged to challenge previous thinking about screening for cognitive impairment. Consequently, changes have occurred in health care policies and priorities, including the establishment of the annual wellness visit, which requires detection of any cognitive impairment for Medicare enrollees. In response to these changes, the Alzheimer's Foundation of America and the Alzheimer's Drug Discovery Foundation convened a workgroup to review evidence for screening implementation and to evaluate the implications of routine dementia detection for health care redesign. The primary domains reviewed were consideration of the benefits, harms, and impact of cognitive screening on health care quality. In conference, the workgroup developed 10 recommendations for realizing the national policy goals of early detection as the first step in improving clinical care and ensuring proactive, patient-centered management of dementia.

Original language	English (US)
Pages (from-to)	151-159
Number of pages	9
Journal	Alzheimer's and Dementia
Volume	9
Issue number	2
DOIs	https://doi.org/10.1016/j.jalz.2012.08.008
State	Published - Mar 2013

Bibliographical note

Funding Information:
Dr Boustani was a scientific consultant who advised United BioSource Corporation on the development of their physician survey. Dr Morris is supported by National Institute on Aging grant no. P50AG05681 .

Keywords

Alzheimer
Annual wellness visit
Cognitive impairment
Cost-benefit analysis
Dementia
Detection
Health care
Management
Medicare
Patient-centered
Policy
Priority
Quality
Screening

Access

10.1016/j.jalz.2012.08.008

OpenUrl availability

Full text

Cite this

Borson, S., Frank, L., Bayley, P. J., Boustani, M., Dean, M., Lin, P. J., McCarten, J. R., Morris, J. C., Salmon, D. P., Schmitt, F. A., Stefanacci, R. G., Mendiondo, M. S., Peschin, S., Hall, E. J., Fillit, H., & Ashford, J. W. (2013). Improving dementia care: The role of screening and detection of cognitive impairment. Alzheimer's and Dementia, 9(2), 151-159. https://doi.org/10.1016/j.jalz.2012.08.008

Borson, S, Frank, L, Bayley, PJ, Boustani, M, Dean, M, Lin, PJ, McCarten, JR, Morris, JC, Salmon, DP, Schmitt, FA, Stefanacci, RG, Mendiondo, MS, Peschin, S, Hall, EJ, Fillit, H & Ashford, JW 2013, 'Improving dementia care: The role of screening and detection of cognitive impairment', Alzheimer's and Dementia, vol. 9, no. 2, pp. 151-159. https://doi.org/10.1016/j.jalz.2012.08.008

@article{b3beae62eafd480dab2d6e4629961bc8,

title = "Improving dementia care: The role of screening and detection of cognitive impairment",

abstract = "The value of screening for cognitive impairment, including dementia and Alzheimer's disease, has been debated for decades. Recent research on causes of and treatments for cognitive impairment has converged to challenge previous thinking about screening for cognitive impairment. Consequently, changes have occurred in health care policies and priorities, including the establishment of the annual wellness visit, which requires detection of any cognitive impairment for Medicare enrollees. In response to these changes, the Alzheimer's Foundation of America and the Alzheimer's Drug Discovery Foundation convened a workgroup to review evidence for screening implementation and to evaluate the implications of routine dementia detection for health care redesign. The primary domains reviewed were consideration of the benefits, harms, and impact of cognitive screening on health care quality. In conference, the workgroup developed 10 recommendations for realizing the national policy goals of early detection as the first step in improving clinical care and ensuring proactive, patient-centered management of dementia.",

keywords = "Alzheimer, Annual wellness visit, Cognitive impairment, Cost-benefit analysis, Dementia, Detection, Health care, Management, Medicare, Patient-centered, Policy, Priority, Quality, Screening",

author = "Soo Borson and Lori Frank and Bayley, {Peter J.} and Malaz Boustani and Marge Dean and Lin, {Pei Jung} and McCarten, {J. Riley} and Morris, {John C.} and Salmon, {David P.} and Schmitt, {Frederick A.} and Stefanacci, {Richard G.} and Mendiondo, {Marta S.} and Susan Peschin and Hall, {Eric J.} and Howard Fillit and Ashford, {J. Wesson}",

note = "Funding Information: Dr Boustani was a scientific consultant who advised United BioSource Corporation on the development of their physician survey. Dr Morris is supported by National Institute on Aging grant no. P50AG05681 . ",

year = "2013",

month = mar,

doi = "10.1016/j.jalz.2012.08.008",

language = "English (US)",

volume = "9",

pages = "151--159",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Improving dementia care

T2 - The role of screening and detection of cognitive impairment

AU - Borson, Soo

AU - Frank, Lori

AU - Bayley, Peter J.

AU - Boustani, Malaz

AU - Dean, Marge

AU - Lin, Pei Jung

AU - McCarten, J. Riley

AU - Morris, John C.

AU - Salmon, David P.

AU - Schmitt, Frederick A.

AU - Stefanacci, Richard G.

AU - Mendiondo, Marta S.

AU - Peschin, Susan

AU - Hall, Eric J.

AU - Fillit, Howard

AU - Ashford, J. Wesson

N1 - Funding Information: Dr Boustani was a scientific consultant who advised United BioSource Corporation on the development of their physician survey. Dr Morris is supported by National Institute on Aging grant no. P50AG05681 .

PY - 2013/3

Y1 - 2013/3

N2 - The value of screening for cognitive impairment, including dementia and Alzheimer's disease, has been debated for decades. Recent research on causes of and treatments for cognitive impairment has converged to challenge previous thinking about screening for cognitive impairment. Consequently, changes have occurred in health care policies and priorities, including the establishment of the annual wellness visit, which requires detection of any cognitive impairment for Medicare enrollees. In response to these changes, the Alzheimer's Foundation of America and the Alzheimer's Drug Discovery Foundation convened a workgroup to review evidence for screening implementation and to evaluate the implications of routine dementia detection for health care redesign. The primary domains reviewed were consideration of the benefits, harms, and impact of cognitive screening on health care quality. In conference, the workgroup developed 10 recommendations for realizing the national policy goals of early detection as the first step in improving clinical care and ensuring proactive, patient-centered management of dementia.

AB - The value of screening for cognitive impairment, including dementia and Alzheimer's disease, has been debated for decades. Recent research on causes of and treatments for cognitive impairment has converged to challenge previous thinking about screening for cognitive impairment. Consequently, changes have occurred in health care policies and priorities, including the establishment of the annual wellness visit, which requires detection of any cognitive impairment for Medicare enrollees. In response to these changes, the Alzheimer's Foundation of America and the Alzheimer's Drug Discovery Foundation convened a workgroup to review evidence for screening implementation and to evaluate the implications of routine dementia detection for health care redesign. The primary domains reviewed were consideration of the benefits, harms, and impact of cognitive screening on health care quality. In conference, the workgroup developed 10 recommendations for realizing the national policy goals of early detection as the first step in improving clinical care and ensuring proactive, patient-centered management of dementia.

KW - Alzheimer

KW - Annual wellness visit

KW - Cognitive impairment

KW - Cost-benefit analysis

KW - Dementia

KW - Detection

KW - Health care

KW - Management

KW - Medicare

KW - Patient-centered

KW - Policy

KW - Priority

KW - Quality

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=84875369850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875369850&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2012.08.008

DO - 10.1016/j.jalz.2012.08.008

M3 - Comment/debate

C2 - 23375564

AN - SCOPUS:84875369850

SN - 1552-5260

VL - 9

SP - 151

EP - 159

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 2

ER -

Improving dementia care: The role of screening and detection of cognitive impairment

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this